Goldman Takes Haemonetics Off Sell List, Upgrades To Neutral

Loading...
Loading...
Goldman Sachs has upgraded Haemonetics Corporation
HAE
to Neutral and removed the stock from Americas Sell List, saying that "consensus numbers and management expectations appear rebased with risk/reward in the stock more balanced." The healthcare company recently issued its fiscal 2017 forecast that calls for adjusted earnings of $1.40-$1.50 per share (Street: $1.42) on revenue of $850 million - $875 million (Street: $888.52 million), 4-7 percent below prior year revenue. For the fourth quarter ended in March, the company's earnings and sales lagged consensus estimates. "While we do not see a case to be more bullish on the stock, we no longer see a justification for an outright bearish view either," analyst David Roman wrote in a note. Looking ahead, the analyst said abating headwinds in blood management and new product launches could boost top-line growth. For FY17, the analyst sees EPS of $1.51, above the company's guidance range. Roman, who also raised his price target to $29 from $25, said: "To become more constructive, we would look for evidence of top-line upside drivers, greater realization of cost savings efforts, and/or balance sheet utilization." At the time of writing, shares of Haemonetics rose 2.87 percent to $26.89.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsUpgradesPrice TargetAnalyst Ratings
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...